What are our pharmacotherapeutic options for MERS-CoV?

Taking stock of the first 133 MERS coronavirus cases globally – Is the epidemic changing?

(2013) P Penttinen et al.   Eurosurveillance

Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy

(2013) Hisham Momattin et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-  treatment

(2013) A. H. de Wilde et al.   JOURNAL OF GENERAL VIROLOGY

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus

(2013) Jasper F.W. Chan et al.   JOURNAL OF INFECTION

An Animal Model of MERS Produced by Infection of Rhesus Macaques With MERS Coronavirus

(2013) Y. Yao et al.   JOURNAL OF INFECTIOUS DISEASES

Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody

(2013) K. Ohnuma et al.   JOURNAL OF VIROLOGY

Human Cell Tropism and Innate Immune System Interactions of Human Respiratory Coronavirus EMC Compared to Those of Severe Acute Respiratory Syndrome Coronavirus

(2013) F. Zielecki et al.   JOURNAL OF VIROLOGY

Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection

(2013) Christian Drosten et al.   LANCET INFECTIOUS DISEASES

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

(2013) V. Stalin Raj et al.   NATURE

Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques

(2013) Darryl Falzarano et al.   NATURE MEDICINE

Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques

(2013) E. de Wit et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficient Replication of the Novel Human Betacoronavirus EMC on Primary Human Epithelium Highlights Its Zoonotic Potential

(2013) E. Kindler et al.   mBio

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin

(2013) Darryl Falzarano et al.   Scientific Reports

Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics

(2013) Everett Clinton Smith et al.   PLoS Pathogens

The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus Inhibitors

(2011) Susanne Pfefferle et al.   PLoS Pathogens